BriaCell files routine Q2 2026 financials via Canadian subsidiary disclosure

Filed March 31, 2026 · Period ending March 31, 2026 · ~1 min read

Key Changes

• low

  BriaPro Therapeutics, BriaCell's subsidiary, filed unaudited financial statements and management discussion for the three and six months ended January 31, 2026 with British Columbia and Alberta securities regulators.

  Item 8.01 view on EDGAR →
• low

  Filing made under Regulation FD to ensure U.S. investors have access to the same quarterly financial information disclosed in Canada.

  8-K: Reg FD Disclosure verify on EDGAR →